- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Psyence Group Inc: Psyence associate appoints Stein to advisory board | 1 | Stockwatch | ||
| 25.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein | 1 | GlobeNewswire (USA) | ||
| 10.03. | Psyence Group Inc: Psyence associate adds Garcia-Romeu as chair of SAB | 1 | Stockwatch | ||
| 10.03. | Psyence Group announces collaboration with Johns Hopkins researcher | 1 | Investing.com | ||
| 10.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board | 143 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM"... ► Artikel lesen | |
| PSYENCE GROUP Aktie jetzt für 0€ handeln | |||||
| 23.12.24 | Psyence Unveils Private Placement | - | Baystreet.ca | ||
| 06.12.24 | Psyence Group Inc: Psyence to receive Psyence Biomedical shares for debt | 2 | Stockwatch | ||
| 06.12.24 | Psyence Group Inc.: Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations | 1 | GlobeNewswire (USA) | ||
| 31.10.24 | Psyence Group Inc: Psyence Group closes sale of PsyLabs interest | 1 | Stockwatch | ||
| 31.10.24 | Psyence Group Inc.: Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs | 158 | GlobeNewswire (Europe) | PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence... ► Artikel lesen | |
| 25.10.24 | Psyence Group Inc: Psyence Group adds Empax Center as clinical trial site | 1 | Stockwatch | ||
| 25.10.24 | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care | 3 | GlobeNewswire (USA) | ||
| 15.10.24 | Psyence Group Inc: Psyence Group, Psyence Biomed enter debt swap deal | 3 | Stockwatch | ||
| 14.10.24 | Psyence Group Inc.: Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical | 151 | GlobeNewswire (Europe) | TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap... ► Artikel lesen | |
| 20.09.24 | Psyence Group Inc.: Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs | 812 | GlobeNewswire (Europe) | NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) (as seller), a life science biotechnology company pioneering the use of nature-derived... ► Artikel lesen | |
| 18.09.24 | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones | 193 | GlobeNewswire (Europe) | Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,965 | +2,27 % | Biotech Report: Kursgewinne bei Evotec und Qiagen | (shareribs.com) Frankfurt / New York 01.04.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend fester. Hierzulande legen unter anderem Biontech und Evotec zu. An der Wall Street sind die... ► Artikel lesen | |
| TEMPUS AI | 37,250 | -12,76 % | Tempus AI, Inc. (TEM): Among Stocks That Will Profit From AI | ||
| EVOTEC | 5,700 | +9,03 % | BASF, Evotec, LPKF Laser, Medigene, Rheinmetall, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIONTECH | 81,10 | +4,51 % | BioNTech-Aktie: Das ist grotesk! | News von Trading-Treff.de BioNTech ist in einer grotesken Verfassung. Die Mainzer haben immerhin am Dienstag nun einen Aufschlag um fast 0,5 % geschafft. Dabei sind die Notierungen auf 84,45 Euro geklettert.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,970 | -5,70 % | Recursion Pharmaceuticals: Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas | Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first... ► Artikel lesen | |
| BEAM THERAPEUTICS | 14,530 | -5,00 % | Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease | ||
| MODERNA | 22,520 | -4,15 % | Zollängste dämpfen die Stimmung - Gold, Apple, Amazon, Altria, Visa, PVH, Dollar General, Moderna | Nach einem schwachen Start konnte sich die Wall Street im Verlauf des gestrigen Handels teilweise erholen, ging jedoch uneinheitlich aus dem Handel. Die Nervosität unter den Anlegern bleibt spürbar... ► Artikel lesen | |
| ZYVERSA THERAPEUTICS | 1,270 | +102,33 % | ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) | WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
| BB BIOTECH | 28,800 | +1,41 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| CUREVAC | 2,468 | +1,82 % | CureVac-Aktie: Donnerschlag! | News von Trading-Treff.de Die CureVac-Aktie ist am Donnerstag um rund 1,2 % gestiegen. Am Vorabend war es in den USA an der Nasdaq bereits um mehr als 5 % aufwärts gegangen. Dabei hat die Aktie aus... ► Artikel lesen | |
| 2SEVENTY BIO | 4,885 | -1,21 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| STRYKER | 304,00 | -3,92 % | Stryker Sells U.S. Spinal Implants Business To Viscogliosi Brothers, Forms VB Spine | WASHINGTON (dpa-AFX) - Stryker (SYK) Tuesday has finalized the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, forming the new company VB Spine, LLC. This move aligns... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 35,720 | -3,43 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 11,500 | -2,87 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 28,880 | -10,31 % | Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results | Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)... ► Artikel lesen |
Das Unternehmen PSYENCE GROUP INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE GROUP INC finden Sie auf Wallstreet Online.
